undamentalytics Newsletter
Sign in

Lipocine Inc. balance sheet

At the end of fiscal 2025, Lipocine Inc. had total assets of $17.0m, total liabilities of $2.5m and shareholders' equity of $14.5m. It held $5.2m in cash against $0 of debt: net cash of $5.2m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents5456381019335655
Total current assets5462725212025463423221724
Total assets6462725212025523823231724
Accounts payable0101112111011
Total current liabilities0116457623232
Short-term debt———03332—————
Long-term debt———07422—————
Total debt000010762—0000
Total liabilities0116111310723232
Shareholders' equity54526199615463620211422
Net debt (negative = net cash)−5−45−6−32−3−14−1−3−5−6−5−5
Shares outstanding————————5m5m5m6m8m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: LPCN vs NTRBLPCN vs SXTCLPCN vs SXTPLPCN vs SCNX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Lipocine Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lipocine Inc.